Aditxt Implements 1-for-113 Reverse Stock Split to Maintain Nasdaq Listing
TL;DR
Aditxt's reverse stock split could boost share price to meet Nasdaq requirements, potentially attracting new investors and stabilizing the company's market position.
Aditxt will execute a 1-for-113 reverse stock split on November 3, 2025, converting every 113 shares into one share with fractional shares rounded up.
This financial restructuring supports Aditxt's mission to accelerate health innovations that address autoimmune diseases, cancer detection, and women's health challenges globally.
Aditxt's dramatic 1-for-113 reverse split demonstrates how companies use creative financial strategies to maintain their Nasdaq listing while pursuing medical breakthroughs.
Found this article helpful?
Share it with your network and spread the knowledge!
Aditxt Inc. (NASDAQ: ADTX) will implement a significant 1-for-113 reverse stock split of its common stock effective at the opening of trading on November 3, 2025. The biotechnology company's shares will continue trading under the same ADTX symbol following this corporate action. This substantial consolidation means every 113 shares of issued and outstanding common stock will convert into one share, with the company implementing a rounding-up mechanism for fractional shares.
The reverse stock split represents a critical strategic move for Aditxt, specifically designed to help the company regain compliance with Nasdaq's minimum bid price requirement. Stockholders previously approved this measure on September 23, 2025, demonstrating shareholder support for maintaining the company's Nasdaq listing status. The minimum bid price requirement is a fundamental Nasdaq listing standard that mandates companies maintain a share price above $1.00, and failure to meet this standard can result in delisting from the exchange.
For investors, this corporate action carries significant implications. While the reverse split does not fundamentally change the company's market capitalization, it substantially reduces the number of outstanding shares and proportionally increases the share price. This maneuver is particularly important for maintaining institutional investor interest, as many investment funds have policies against holding stocks trading below certain price thresholds. The company's full press release detailing this corporate action is available at https://ibn.fm/KgRGL.
Aditxt operates as a social innovation platform focused on accelerating promising health innovations across multiple therapeutic areas. The company's current programs target autoimmunity, cancer and early disease detection, infectious diseases, and women's health. Investors seeking ongoing updates about Aditxt's developments can access the company's newsroom at https://ibn.fm/ADTX.
The timing of this reverse split coincides with Aditxt's broader strategic initiatives in the competitive biotechnology sector. Maintaining Nasdaq listing status is crucial for the company's ability to raise capital, attract institutional investors, and provide liquidity for existing shareholders. For the broader market, this action highlights the challenges faced by early-stage biotechnology companies in maintaining exchange listing requirements while advancing their research and development programs. The reverse stock split represents a necessary step for Aditxt to preserve its public market presence as it continues developing its health innovation platform.
Curated from InvestorBrandNetwork (IBN)
